Explore
Validate
Learn
Western blot
ImmunoprecipitationAntibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-12885 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-ErbB4 Monoclonal Antibody (H4.77.16 (Ab77)), Biotin
- Antibody type
- Monoclonal
- Antigen
- Recombinant protein fragment
- Description
- MA5-12888 targets HER-4 in Western blot, flow cytometry and immunoprecipitation applications and shows reactivity with Human, mouse, and Rat samples. The MA5-12888 immunogen is extracellular fragment of recombinant human c-erbB-4/HER-4 oncoprotein.
- Reactivity
- Human, Mouse, Rat
- Host
- Mouse
- Conjugate
- Biotin
- Isotype
- IgG
- Antibody clone number
- H4.77.16 (Ab77)
- Vial size
- 500 µL
- Concentration
- 0.2 mg/ml
- Storage
- 4° C
Submitted references Neuregulin 1 confers neuroprotection in SOD1-linked amyotrophic lateral sclerosis mice via restoration of C-boutons of spinal motor neurons.
Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.
Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons.
Gene expression and immunolocalization of heparin-binding epidermal growth factor-like growth factor and human epidermal growth factor receptors in human corpus luteum.
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Regulation of ErbB4 phosphorylation and cleavage by a novel histidine acid phosphatase.
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer.
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
Lasiene J, Komine O, Fujimori-Tonou N, Powers B, Endo F, Watanabe S, Shijie J, Ravits J, Horner P, Misawa H, Yamanaka K
Acta neuropathologica communications 2016 Feb 18;4:15
Acta neuropathologica communications 2016 Feb 18;4:15
Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin.
Parente-Pereira AC, Whilding LM, Brewig N, van der Stegen SJ, Davies DM, Wilkie S, van Schalkwyk MC, Ghaem-Maghami S, Maher J
Journal of immunology (Baltimore, Md. : 1950) 2013 Sep 1;191(5):2437-45
Journal of immunology (Baltimore, Md. : 1950) 2013 Sep 1;191(5):2437-45
Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).
Jay JI, Brunhoeber PS, Smith MH, Williams RR, Sugarman MC, Free HL, Tast DE
Histopathology 2013 Mar;62(4):563-77
Histopathology 2013 Mar;62(4):563-77
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.
Davies DM, Foster J, Van Der Stegen SJ, Parente-Pereira AC, Chiapero-Stanke L, Delinassios GJ, Burbridge SE, Kao V, Liu Z, Bosshard-Carter L, Van Schalkwyk MC, Box C, Eccles SA, Mather SJ, Wilkie S, Maher J
Molecular medicine (Cambridge, Mass.) 2012 May 9;18:565-76
Molecular medicine (Cambridge, Mass.) 2012 May 9;18:565-76
Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons.
Longart M, Chatani-Hinze M, Gonzalez CM, Vullhorst D, Buonanno A
Brain research bulletin 2007 Jul 12;73(4-6):210-9
Brain research bulletin 2007 Jul 12;73(4-6):210-9
Gene expression and immunolocalization of heparin-binding epidermal growth factor-like growth factor and human epidermal growth factor receptors in human corpus luteum.
Akayama Y, Takekida S, Ohara N, Tateiwa H, Chen W, Nakabayashi K, Maruo T
Human reproduction (Oxford, England) 2005 Oct;20(10):2708-14
Human reproduction (Oxford, England) 2005 Oct;20(10):2708-14
Isolation of scFvs to in vitro produced extracellular domains of EGFR family members.
Horak E, Heitner T, Robinson MK, Simmons HH, Garrison J, Russeva M, Furmanova P, Lou J, Zhou Y, Yuan QA, Weiner LM, Adams GP, Marks JD
Cancer biotherapy & radiopharmaceuticals 2005 Dec;20(6):603-13
Cancer biotherapy & radiopharmaceuticals 2005 Dec;20(6):603-13
Regulation of ErbB4 phosphorylation and cleavage by a novel histidine acid phosphatase.
Fleisig H, El-Din El-Husseini A, Vincent SR
Neuroscience 2004;127(1):91-100
Neuroscience 2004;127(1):91-100
HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.
Dragowska WH, Warburton C, Yapp DT, Minchinton AI, Hu Y, Waterhouse DN, Gelmon K, Skov K, Woo J, Masin D, Huxham LA, Kyle AH, Bally MB
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Molecular cancer research : MCR 2004 Nov;2(11):606-19
Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer.
Shirakawa K, Tsuda H, Heike Y, Kato K, Asada R, Inomata M, Sasaki H, Kasumi F, Yoshimoto M, Iwanaga T, Konishi F, Terada M, Wakasugi H
Cancer research 2001 Jan 15;61(2):445-51
Cancer research 2001 Jan 15;61(2):445-51
Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2.
Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, Doihara H, Shimizu N, Sonoo H
British journal of cancer 2000 Jan;82(1):46-51
British journal of cancer 2000 Jan;82(1):46-51
Reversal of HER-2 over-expression renders human ovarian cancer cells highly resistant to taxol.
Aigner A, Hsieh SS, Malerczyk C, Czubayko F
Toxicology 2000 Apr 3;144(1-3):221-8
Toxicology 2000 Apr 3;144(1-3):221-8
Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo.
Tang CK, Concepcion XZ, Milan M, Gong X, Montgomery E, Lippman ME
Cancer research 1999 Oct 15;59(20):5315-22
Cancer research 1999 Oct 15;59(20):5315-22
ErbB-4 ribozymes abolish neuregulin-induced mitogenesis.
Tang CK, Goldstein DJ, Payne J, Czubayko F, Alimandi M, Wang LM, Pierce JH, Lippman ME
Cancer research 1998 Aug 1;58(15):3415-22
Cancer research 1998 Aug 1;58(15):3415-22
No comments: Submit comment
No validations: Submit validation data